Myeloperoxidase (fl*0,5ml) Cell Marque

Myeloperoxidase (fl*0,5ml) Cell Marque Cantitatile min./ max.acord cadru sunt in caietul de sarcini .Frecventa celui mai mare contr.subsesvent cu val.max. estimata ce urmeaza a fi achizitionate pe durata intregului acord cadru (dupa necesitati) conf.datelor /lot SICAP din F.D.& anexa. (cant.&val.min/max) Oferta se dep./lot respect.cant./caract & conditiile.produs.conf.caiet de sarcini.In cazul care se constata ca ofertele admisibile clasate pe primele 5 locuri au preturi egale A.C.va solicita reofertari.pt.departajare fara sa afecteze pozitiile superioare in clasament. Se vor efectua ctr. subsecvente semestriale pe perioada acordului –cadru 36luni. Cerintele tehnice definite la nivelul anuntului de participare, caietului de sarcini sau altor documente complementare, prin trimiterea standardelor, la un anumit producator, la marci, brevete, tipuri, la o origine sau la o productie/metoda specifica de fabricatie/prestare/executie, vor fi intelese ca fiind insotite de mentiunea ”sau echivalent”(dupa caz) false false

Related documents

• Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)#1032448
• Myeloperoxidase (MPO) Inhibitor A_Zeneca for Heart Failure With Preserved Ejection Fraction (HFpEF)#1125124
• Gemtuzumab ozogamicin as postconsolidation therapy does not prevent relapse in children with AML: results from NOPHO-AML 2004#1166729
• Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia#899354
• Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations#295978